Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare autosomal dominant syndrome linked to mutations in the PITX2 gene. It is characterized by abnormalities in the anterior chamber of the eye and underdevelopment of the teeth.
Features include always present findings: Ectopia pupillae, Thin upper lip vermilion, Oligodontia, and Microdontia and others. 23 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 2 | Strabismus, Glaucoma |
Head and neck |
PITX2 function has not been fully characterized.
Axenfeld-Rieger syndrome type 1 is associated with mutations in the PITX2 gene on chromosome 4.
Genetic testing for PITX2 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 6 always present features.
No clinical trials have been registered for Axenfeld-Rieger syndrome type 1.
17 publications have been identified in PubMed for Axenfeld-Rieger syndrome type 1. Research spans Case Report / Case Series (35%), Basic Science / Preclinical (35%), and Review / Meta-Analysis (18%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 6 | 35% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 3:00 PM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about Axenfeld-Rieger syndrome type 1
2 |
Thin upper lip vermilion, Hypoplasia of the maxilla |
Hormones | 1 | Decreased response to growth hormone stimulation test |
Growth and development | 1 | Decreased response to growth hormone stimulation test |
Laboratory research
6 |
35% |
Research summaries | 3 | 18% |
Other research | 1 | 6% |
Disease patterns and progression | 1 | 6% |
Mitchell LA (2026). [PMID: 41888561](https://pubmed.ncbi.nlm.nih.gov/41888561/). *Eur J Hum Genet*. [Basic Science / Preclinical]
Bremond-Gignac D (2026). [PMID: 41455383](https://pubmed.ncbi.nlm.nih.gov/41455383/). *J Fr Ophtalmol*. [Review / Meta-Analysis]
Moraes PC (2026). [PMID: 41913912](https://pubmed.ncbi.nlm.nih.gov/41913912/). *Int Med Case Rep J*. [Case Report / Case Series]
Tripathy K (2026). [PMID: 30860739](https://pubmed.ncbi.nlm.nih.gov/30860739/). *Unknown Journal*. [Other]
Mitchell LA (2025). [PMID: 40502565](https://pubmed.ncbi.nlm.nih.gov/40502565/). *medRxiv*. [Basic Science / Preclinical]
Kotecha MR (2025). [PMID: 41348369](https://pubmed.ncbi.nlm.nih.gov/41348369/). *Ann Afr Med*. [Case Report / Case Series]
Vetriselvan Y (2025). [PMID: 38802693](https://pubmed.ncbi.nlm.nih.gov/38802693/). *Biochem Genet*. [Basic Science / Preclinical]
Ohkubo Y (2025). [PMID: 40741157](https://pubmed.ncbi.nlm.nih.gov/40741157/). *Radiol Case Rep*. [Case Report / Case Series]
Hall J (2025). [PMID: 40138169](https://pubmed.ncbi.nlm.nih.gov/40138169/). *Ophthalmol Ther*. [Review / Meta-Analysis]
Schuknecht A (2025). [PMID: 39870091](https://pubmed.ncbi.nlm.nih.gov/39870091/). *Klin Monbl Augenheilkd*. [Epidemiology / Natural History]
AI-curated news mentioning Axenfeld-Rieger syndrome type 1
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.